About galera therapeutics inc - GRTX
Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. It is also involved in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis, and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
GRTX At a Glance
Galera Therapeutics, Inc.
101 Lindenwood Drive
Malvern, Pennsylvania 19355
| Phone | 1-610-725-1500 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | 149.05M | |
| Sector | Health Technology | Employees | 3 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GRTX Valuation
| P/E Current | 0.03 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 0.015 |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.418 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.27 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
GRTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | 49,683,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GRTX Liquidity
| Current Ratio | 11.00 |
| Quick Ratio | 11.00 |
| Cash Ratio | 9.884 |
GRTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | 1,723.409 |
| Return on Equity | N/A |
| Return on Total Capital | 2,275.21 |
| Return on Invested Capital | 2,139.818 |
GRTX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |